Cell membrane coated nanoparticles as a biomimetic drug delivery platform for enhancing cancer immunotherapy

被引:6
作者
Zhong, Zichen [1 ]
Deng, Wen [1 ]
Wu, Jian [1 ]
Shang, Haojie [1 ]
Tong, Yonghua [1 ]
He, Yu [1 ]
Huang, Qiu [1 ]
Ba, Xiaozhuo [1 ]
Chen, Zhiqiang [1 ]
Tang, Kun [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan 430030, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
POLYMERIC NANOPARTICLES; EXTRACELLULAR VESICLES; ANTICANCER VACCINATION; MAGNETIC NANOPARTICLES; TUMOR; THERAPY; NANOVACCINE; RESISTANCE; MICROENVIRONMENT; NANOSYSTEM;
D O I
10.1039/d4nr00284a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Cancer immunotherapy, a burgeoning modality for cancer treatment, operates by activating the autoimmune system to impede the growth of malignant cells. Although numerous immunotherapy strategies have been employed in clinical cancer therapy, the resistance of cancer cells to immunotherapeutic medications and other apprehensions impede the attainment of sustained advantages for most patients. Recent advancements in nanotechnology for drug delivery hold promise in augmenting the efficacy of immunotherapy. However, the efficacy is currently constrained by the inadequate specificity of delivery, low rate of response, and the intricate immunosuppressive tumor microenvironment. In this context, the investigation of cell membrane coated nanoparticles (CMNPs) has revealed their ability to perform targeted delivery, immune evasion, controlled release, and immunomodulation. By combining the advantageous features of natural cell membranes and nanoparticles, CMNPs have demonstrated their unique potential in the realm of cancer immunotherapy. This review aims to emphasize recent research progress and elucidate the underlying mechanisms of CMNPs as an innovative drug delivery platform for enhancing cancer immunotherapy. Additionally, it provides a comprehensive overview of the current immunotherapeutic strategies involving different cell membrane types of CMNPs, with the intention of further exploration and optimization. Graphical abstract of CMNPs delivering different therapeutic agents for enhancing cancer immunotherapy.
引用
收藏
页码:8708 / 8738
页数:31
相关论文
共 217 条
  • [1] Engineered Nanoparticles for Cancer Vaccination and Immunotherapy
    Aikins, Marisa E.
    Xu, Cheng
    Moon, James J.
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 2020, 53 (10) : 2094 - 2105
  • [2] Liposomal drug delivery systems: From concept to clinical applications
    Allen, Theresa M.
    Cullis, Pieter R.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) : 36 - 48
  • [3] Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite"
    Arina, Ainhoa
    Gutiontov, Stanley I.
    Weichselbaum, Ralph R.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (12) : 2777 - 2782
  • [4] Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
    Au, Lewis
    Hatipoglu, Emine
    de Massy, Marc Robert
    Litchfield, Kevin
    Beattie, Gordon
    Rowan, Andrew
    Schnidrig, Desiree
    Thompson, Rachael
    Byrne, Fiona
    Horswell, Stuart
    Fotiadis, Nicos
    Hazell, Steve
    Nicol, David
    Shepherd, Scott T. C.
    Fendler, Annika
    Mason, Robert
    Del Rosario, Lyra
    Edmonds, Kim
    Lingard, Karla
    Sarker, Sarah
    Mangwende, Mary
    Carlyle, Eleanor
    Attig, Jan
    Joshi, Kroopa
    Uddin, Imran
    Becker, Pablo D.
    Sunderland, Mariana Werner
    Akarca, Ayse
    Puccio, Ignazio
    Yang, William W.
    Lund, Tom
    Dhillon, Kim
    Vasquez, Marcos Duran
    Ghorani, Ehsan
    Xu, Hang
    Spencer, Charlotte
    Lopez, Jose, I
    Green, Anna
    Mahadeva, Ula
    Borg, Elaine
    Mitchison, Miriam
    Moore, David A.
    Proctor, Ian
    Falzon, Mary
    Pickering, Lisa
    Furness, Andrew J. S.
    Reading, James L.
    Salgado, Roberto
    Marafioti, Teresa
    Jamal-Hanjani, Mariam
    [J]. CANCER CELL, 2021, 39 (11) : 1497 - +
  • [5] Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
    Bagchi, Sreya
    Yuan, Robert
    Engleman, Edgar G.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 : 223 - 249
  • [6] Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors
    Bahmani, Baharak
    Gong, Hua
    Luk, Brian T.
    Haushalter, Kristofer J.
    DeTeresa, Ethel
    Previti, Mark
    Zhou, Jiarong
    Gao, Weiwei
    Bui, Jack D.
    Zhang, Liangfang
    Fang, Ronnie H.
    Zhang, Jie
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [7] Chemo-immunotherapy with doxorubicin prodrug and erythrocyte membrane-enveloped polymer nano-vaccine enhances antitumor activity
    Bao, Yuling
    Hu, Qian
    Wang, Xiuping
    Feng, Xiaobo
    He, Yu
    Guo, Yuanyuan
    Fu, Dehao
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2020, 129
  • [8] Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
    Baxi, Shrujal
    Yang, Annie
    Gennarelli, Renee L.
    Khan, Niloufer
    Wang, Ziwei
    Boyce, Lindsay
    Korenstein, Deborah
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 360
  • [9] Challenges and Opportunities for Pancreatic Cancer Immunotherapy
    Bear, Adham S.
    Vonderheide, Robert H.
    O'Hara, Mark H.
    [J]. CANCER CELL, 2020, 38 (06) : 788 - 802
  • [10] An overview of synthesis, characterization, applications and associated adverse effects of bioactive nanoparticles
    Bommakanti, Vaishnavi
    Banerjee, Madhura
    Shah, Divik
    Manisha, Kowdi
    Sri, Kavya
    Banerjee, Satarupa
    [J]. ENVIRONMENTAL RESEARCH, 2022, 214